TY  - JOUR
AU  - Argiles, Guillem
AU  - Mulet, Nuria
AU  - Valladares-Ayerbes, Manuel
AU  - Vieitez, Jose M
AU  - Gravalos, Cristina
AU  - Garcia-Alfonso, Pilar
AU  - Santos, Cristina
AU  - Tobeña, Maria
AU  - Garcia-Paredes, Beatriz
AU  - Benavides, Manuel
AU  - Cano, María T
AU  - Loupakis, Fotios
AU  - Rodriguez-Garrote, Mercedes
AU  - Rivera, Fernando
AU  - Goldberg, Richard M
AU  - Cremolini, Chiara
AU  - Bennouna, Jaafar
AU  - Ciardiello, Fortunato
AU  - Tabernero, Josep M
AU  - Aranda, Enrique
PY  - 2022
DO  - 10.1016/j.ejca.2022.09.037
UR  - http://hdl.handle.net/10668/22181
T2  - European journal of cancer (Oxford, England : 1990)
AB  - The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients. Patients with mCRC and progression during or within 3 months following their last standard...
LA  - en
PB  - Elsevier
KW  - Colorectal cancer
KW  - Drug administration schedule
KW  - Metastasis
KW  - Regorafenib
KW  - Humans
KW  - Phenylurea compounds
KW  - Pyridines
KW  - Colorectal neoplasms
KW  - Colonic neoplasms
KW  - Rectal neoplasms
TI  - A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).
TY  - research article
VL  - 177
ER  -